Our work in TB-HIV, TB-Diabetes and co-morbidities
The Union develops, tests, implements and scales up models of care for co-morbid conditions that increase the risk of developing TB, that are prevalent in high TB burden settings, or that adversely affect TB treatment outcomes.
Integrated HIV Care Programme - Myanmar
Through its Integrated HIV Care (IHC) Programme, The Union Office in Myanmar currently provides services to nearly 34,000 People Living with HIV, more than 33,400 of which are taking antiretroviral treatment.
OTHER AREAS OF OUR WORK IN TUBERCULOSIS
You might also be interested in our work on child and adolescent TB and drug-resistant TB.
TB co-morbidities Union news
The rationale for cancer to be made a notifiable disease in India
In this Short Communication (to be published in the Q2 issue of PHA), the authors explain why the Ministry of Health in India should make cancer a notifiable disease.
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, we present an article that assesses the burden of multimorbidity and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe
Evaluating disability, comorbidities and risk factors after TB treatment: an 18–24 month follow-up in China
Ahead of World TB Day, we present an article that assesses disability, comorbidities and risk factors after TB treatment in China.
TB co-morbidities publications
The rationale for cancer to be made a notifiable disease in India
In this Short Communication (to be published in the Q2 issue of PHA), the authors explain why the Ministry of Health in India should make cancer a notifiable disease.
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, we present an article that assesses the burden of multimorbidity and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe
Evaluating disability, comorbidities and risk factors after TB treatment: an 18–24 month follow-up in China
Ahead of World TB Day, we present an article that assesses disability, comorbidities and risk factors after TB treatment in China.